BioMarin Pharmaceutical (BMRN) : During the past 4 weeks, traders have been relatively bearish on BioMarin Pharmaceutical (BMRN), hence the stock is down -3.12% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.01% relative to the S&P 500. The 4-week change in the price of the stock is -3.24% and the stock has fallen -0.51% in the past 1 week.
The stock has recorded a 20-day Moving Average of 0.96% and the 50-Day Moving Average is 4.55%.The 200 Day SMA reached 8.66%. BioMarin Pharmaceutical Inc. is up 6.94% in the last 3-month period. Year-to-Date the stock performance stands at -8.62%.
BioMarin Pharmaceutical (NASDAQ:BMRN): After opening at $95.3, the stock dipped to an intraday low of $93.86 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $96.49 and the buying power remained strong till the end. The stock closed at $95.73 for the day, a gain of 0.57% for the day session. The total traded volume was 801,788. The stocks close on the previous trading day was $95.19.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).